Systemic lupus erythematosus (SLE) is a complex autoimmune disease. Cytokine gene polymorphisms play an important role in SLE. Thus, this study aimed to investigate the associations between interleukin 6 (IL-6) and interleukin 10 (IL-10) promoter single-nucleotide polymorphisms (SNPs) and their susceptibility to SLE and the implications for plasma levels. We genotyped IL-6-174G/C (rs1800795) using mutagenically separated polymerase chain reaction (MS-PCR) and IL-10-1082G/A (rs1800896) and -819C/T (rs1800871) using sequence specific primer polymerase chain reaction (SSP-PCR) in 100 Egyptian patients and 119 controls. The plasma levels of IL-6 and IL-10 were measured by enzyme-linked immunosorbent assay (ELISA). There was significant increase in the frequency of IL-6 (-174) GG genotype (P < 0.05) and G allele (P < 0.01) compared to controls. A significant increase in the distribution of IL-10 (-1082G/A) GG (P < 0.05) and AA (P < 0.05) genotypes and a significant reduction in the frequency of GA genotype (P < 0.05) was found in SLE patients. The mean serum concentration of IL-6 (P < 0.001) and IL-10 (P < 0.001) was significantly elevated in SLE patients compared to healthy controls. There was no significant association of the most common clinical findings and IL-6 and IL-10 gene polymorphisms in SLE patients. In conclusion, our preliminary study indicated that both GG genotype and G allele of IL-6 (-174G/C) could be considered as risk factors for SLE. In addition, the polymorphisms at IL-10 (-1082 G/G and AA) may play a role in SLE susceptibility in Egyptian patients. Larger prospective studies are needed to confirm our findings.
GrahamDSCAkilMVyseTJ. Association of polymorphism across the tyrosine kinase gene, TYK2 in UK SLE families. Rheumatology2007; 46: 927–930.
3.
LeeYHRhoYHChoiSJ. The PTPN22 C1858T functional polymorphism and autoimmune disease—a meta-analysis. Rheumatology2007; 46: 49–56.
4.
CastroJBaladaEOrdi-RosJVilardell-TarrésM. The complex immunogenetic basis of systemic lupus erythematosus. Autoimmun Rev2008; 7: 345–351.
5.
DanchenkoNSatiaJAAnthonyMS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus2006; 15: 308–318.
6.
XuQianTin SoeKyawSuppiahSivalingamThumbooJKohDRFongKY. Interleukin-18 promoter gene polymorphisms in Chinese patients with systemic lupus erythematosus: association with CC genotype at position -607. Ann Acad Med Singap2007; 36: 91–95.
7.
GröndalGGunnarssonIRönnelidJRogbergSKlareskogLLundbergI. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol2000; 18: 565–570.
8.
SunKHYuCLTangSJSunGH. Monoclonal anti-doublestranded DNA autoantibody stimulates the expression and release of IL-1beta, IL-6, IL-8, IL-10 and TNF-alpha from normal human mononuclear cells involving in the lupus pathogenesis. Immunology2000; 99: 352–360.
9.
SchulerMKSellSAicherWK. Protein kinase signals activate interleukin 16 encoding transcripts in rheumatoid arthritis versus osteoarthritis synovial fibroblasts. Ann Rheum Dis2003; 62: 182–183.
10.
DengJMShiHZ. Interleukin-16 in asthma. Chin Med J2006; 119: 1017–1025.
11.
Palafox-Sánchez CA, Oregon-Romero E, Salazar-Camarena DC, et al. Association of interleukin-10 promoter haplotypes with disease susceptibility and IL-10 levels in Mexican patients with systemic lupus erythematosus. Clin Exp Med 2015; 15: 439--446.
12.
FunauchiMYuHSugiyamaM. Increased interleukin-4 production by NK T cells in systemic lupus erythematosus. Clin Immunol1999; 92: 197–202.
13.
CsiszarANagyGGergelyPPozsonyiTPocsikE. Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol2000; 122: 464–470.
14.
ChunHYChungJWKimHA. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol2007; 27: 461–466.
15.
NakashimaHAkahoshiMMasutaniK. Th1/Th2 balance of SLE patients with lupus nephritis. Rinsho Byori2006; 54: 706–713.
16.
CigniAPileriPVFaeddaR. Interleukin 1, interleukin 6, interleukin 10, and tumor necrosis factor α in active and quiescent systemic lupus erythematosus. J Invest Med2014; 62: 825–829.
17.
MatsushitaT. Regulatory B cells in mouse models of systemic lupus erythematosus (SLE). Methods Mol Biol2014; 1190: 195–205.
18.
SchotteHSchluterBRustSAssmannGDomschkeWGaubitzM. Interleukin-6 promoter polymorphism (-174 G/C) in Caucasian German patients with systemic lupus erythematosus. Rheumatology2001; 40: 393–400.
19.
PapassotiropoulosAHockCNitschRM. Genetics of interleukin 6: implications for Alzheimer’s disease. Neurobiol Aging2001; 22: 863–871.
20.
ChenWFFischerMFrankGZlotnikA. Distinct patterns of lymphokine requirement for the proliferation of various subpopulations of activated thymocytes in a single cell assay. J Immunol1989; 143: 1598–1605.
21.
JeonJYKimHAKimSHParkHSSuhCH. Interleukin 6 Gene polymorphisms are associated with systemic lupus erythematosus in Koreans. J Rheumatol2010; 37: 2251–2258.
22.
FishmanDFauldsGJefferyR. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest1998; 102: 1369–1376.
23.
BombardierCGladmanDDUrowitzMBCaronDChangCH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum1992; 35: 630–640.
24.
MooreKWde Waal MalefytRCoffmanRLO'GarraA. Interleukin-10 and the interleukin-10 receptor. Ann Rev Immunol2001; 19: 683–765.
25.
LalaniIBholKAhmedAR. Interleukin-10: biology, role in inflammation and autoimmunity. Ann Allergy Asthma Immunol1997; 79: 469–483.
26.
McCarthyEMSmithSLeeRZ. The association of cytokines with disease activity and damage scores in systemic lupus erythematosus patients. Rheumatology (Oxford)2014; 53: 1586–1594.
27.
RavirajanCTWangYMatisLA. Effect of neutralizing antibodies to IL-10 and C5 on the renal damage caused by a pathogenic human anti-dsDNA antibody. Rheumatology2004; 43: 442–447.
JohannesonBLimaGvon SalomeJAlarcon-SegoviaDAlarcon- RiquelmeME. A major susceptibility locus for systemic lupus erythematosus maps to chromosome 1q31. Am J Hum Genet2002; 71: 1060–1071.
30.
TurnerDMWilliansDMSankaranDLazarusMSinnotPJHutchinsonIV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet1997; 24: 1–8.
31.
Edwards-SmithCJJonssonJRPurdieDMBansalAShorthouseCPowellEE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology1999; 30: 526–530.
32.
EskdaleJGallagherGVerweijCLKeijsersVWestendorpRGHuizingaTW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA1998; 95: 9465–9470.
33.
TanEMCohenASFriesJF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
34.
AndrejevicSJeremicISefik-BukilicaMNikolicMStojimirovicBBonaci-NikolicB. Immunoserological parameters in SLE: high-avidity anti-dsDNA detected by ELISA are the most closely associated with the disease activity. Clin Rheumatol2013; 32: 1619–1626.
35.
TalaatRMAshourMEBassyouniIHRaoufAA. Polymorphisms of interleukin 6 and interleukin 10 in Egyptian people with Behcet's disease. Immunobiology2014; 219: 573–582.
36.
RustSFunkeHAssmannG. Mutagenically separated PCR (MS-PCR): a highly specific one step procedure for easy mutation detection. Nucleic Acids Res1993; 21: 3623–3629.
37.
PerreyCTurnerSJPravicaVHowellWMHutchinsonIV. ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms. Transpl Immunol1999; 7: 127–128.
38.
HarperJMCookA. Beneficial effects of non-depleting anti-CD4 in MRL/Mp-lpr/lpr mice with active systemic lupus erythematosus and microscopic angiitis. Autoimmunity2001; 33: 245–251.
39.
ChuaKHKeeBPTanSYLianLH. Interleukin-6 promoter polymorphisms (-174 G/C) in Malaysian patients with systemic lupus erythematosus. Brazil J Med Biol Res2009; 42: 551–555.
40.
HrycekASiekieraUCieslikPSzkrobkaW. HLA-DRB1 and - DQB1 alleles and gene polymorphisms of selected cytokines in systemic lupus erythematosus. Rheumatol Int2005; 26: 1–6.
41.
AsanoNMAngeloHDda SilvaHAMaiaMMLinsOGSouzaPE. Interleukin-6 promoter polymorphisms -174 G/C in Brazilian patients with s ystemic lupus erythematosus. Hum Immunol2013; 74: 1153–1156.
42.
HristovaMDourmishevLKamenarskaZ. Role of the promoter polymorphism IL-6 -174G/C in dermatomyositis and systemic lupus erythematosus. Biomed Res Int2013; Epub, doi: 10.1155/2013/315365.
43.
GodarziESarvestaniEAmirghofranZAflakiE. Interleukin-6 gene polymorphism in Iranian patients with systemic lupus erythematosus. Clin Rheumatol2011; 30: 179–184.
44.
SantosMJFernandesDCapelaSda SilvaJCFonsecaJE. Interleukin-6 promoter polymorphism -174 G/C is associated with nephritis in Portuguese Caucasian systemic lupus erythematosus patients. Clin Rheumatol2011; 30: 409–413.
45.
RipleyBJGoncalvesBIsenbergDALatchmanDSRahmanA. Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann Rheum Dis2005; 64: 849–853.
46.
SabryASheashaaHEl-husseiniA. Proinflammatory cytokines (TNF-a and IL-6) in Egyptian patients with SLE: Its correlation with disease activity. Cytokine2006; 35: 148–153.
47.
SaxenaAKhosravianiSNoelSMohanDDonnerTHamadAR. Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine2015; 74: 27–34.
48.
ZhouMDingLPengH. Association of the interleukin-10 gene polymorphism (-1082A/G) with systemic lupus erythematosus: a meta-analysis. Lupus2013; 22: 128–135.
49.
Gwan GyuSongSung JaeChoiJong DaeJiYoung HoLee. Associations between interleukin-10 polymorphisms and susceptibility to systemic lupus erythematosus: A meta-analysis. Human Immunol2013; 74: 364–370.
50.
da SilvaHDda SilvaAPda SilvaHAAsanoNMMaia MdeMde SouzaPR. Interferon gamma and Interleukin 10 polymorphisms in Brazilian patients with systemic lupus erythematosus. Mol Biol Rep2014; 41: 2493–2500.
51.
CrawleyEWooPIsenbergDA. Single nucleotide polymorphic haplotypes of the interleukin-10 5’ flanking region are not associated with renal disease or serology in Caucasian patients with systemic lupus erythematosus. Arthritis Rheum1999; 42: 2017–2018.
52.
van der LindenMWWestendorpRGSturkABergmanWHuizingaTW. High interleukin-10 production in first-degree relatives of patients with generalized but not cutaneous lupus erythematosus. J Investig Med2000; 48: 327–334.
53.
DijstelbloemHMHepkemaBGKallenbergCG. The R-H polymorphism of Fcγ receptor IIa as a risk factor for systemic lupus erythematosus is independent of single-nucleotide polymorphisms in the interleukin-10 gene promoter. Arthritis Rheum2002; 46: 1125–1126.
54.
Guarnizo-ZuccardiPLopezYGiraldoM. Cytokine gene polymorphisms in Colombian patients with systemic lupus erythematosus. Tissue Antigens2007; 70: 376–382.
55.
KurreemanFASchonkerenJJHeijmansBTToesREHuizingaTW. Transcription of the IL10 gene reveals allele-specific regulation at the mRNA level. Human Mol Genet2004; 13: 1755–1762.
56.
LazarusMHajeerAHTurnerD. Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol1997; 24: 2314–2317.
57.
ZhuLJLiuZHZengCHChenZHYuCLiLS. Association of interleukin-10 gene -592 A/C polymorphism with the clinical and pathological diversity of lupus nephritis. Clin Exp Rheumatol2005; 23: 854–860.
58.
MokCCLauCSChanTMWongRW. Clinical characteristics and outcome of southern Chinese males with systemic lupus erythematosus. Lupus1999; 8: 188–196.
59.
RoodMJKeijsersVvan der LindenMW. Neuropsychiatric systemic lupus erythematosus is associated with imbalance in interleukin 10 promoter haplotypes. Ann Rheum Dis1999; 58: 85–89.
60.
FeiGZSvenungssonEFrostegårdJPadyukovL. The A-1087 IL-10 allele is associated with cardiovascular disease in SLE. Atherosclerosis2004; 177: 409–414.
61.
ChongWPIpWKWongWHLauCSChanTMLauYL. Association of interleukin-10 promoter polymorphisms with systemic lupus erythematosus. Genes2004; 5: 484–492.
62.
SungYKParkBLShinHDKimLHKimSYBaeSC. Interleukin-10 gene polymorphisms are associated with the SLICC/ACR Damage Index in systemiclupus erythematosus. Rheumatology (Oxford)2006; 45: 400–404.
63.
Alarcón-RiquelmeMELindqvistAKJonassonI. Genetic analysis of the contribution of IL10 to systemic lupus erythematosus. J Rheumatol1999; 26: 2148–2152.
64.
SuárezALópezPMozoLGutiérrezC. Differential effect of IL10 and TNFα genotypes on determining susceptibility to discoid and systemic lupus erythematosus. Ann Rheum Dis2005; 64: 1605–1610.
65.
LlorenteLRichaud-PatinYGarcía-PadillaC. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum2000; 43: 1790–1800.
66.
LinPWHuangCMHuangCC. The association of -627 interleukin-10 promoter polymorphism in Chinese patients with systemic lupus erythematosus. Clin Rheumatol2007; 26: 298–301.
67.
HoskingLLumsdenSLewisK. Detection of genotyping errors by Hardy–Weinberg equilibrium testing. Euro J Hum Genet2004; 12: 395–399.
68.
BardoczyZGyorffyBKocsisIVásárhelyiB. Re-calculated Hardy–Weinberg values in papers published in Atherosclerosis between 1995 and 2003. Atherosclerosis2004; 173: 141–143.
69.
SalantiGAmountzaGNtzaniEEIoannidisJP. Hardy–Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet2005; 13: 840–848.
